Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Decreased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 61,270 shares of the biopharmaceutical company’s stock after selling 156 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Regeneron Pharmaceuticals were worth $53,813,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in REGN. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter worth approximately $26,000. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. MCF Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $37,000. Finally, Sutton Wealth Advisors Inc. increased its position in Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The disclosure for this sale can be found here. Insiders sold a total of 11,022 shares of company stock worth $10,552,991 over the last quarter. Company insiders own 8.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on REGN. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $7.48 during trading hours on Friday, reaching $883.20. The stock had a trading volume of 505,575 shares, compared to its average volume of 491,077. The company has a market cap of $96.94 billion, a price-to-earnings ratio of 25.63, a PEG ratio of 2.60 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The business’s fifty day moving average is $949.30 and its two-hundred day moving average is $893.27. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the previous year, the firm posted $10.96 EPS. The business’s revenue for the quarter was up .6% on a year-over-year basis. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.